Genetic variation impacts aspirin's effectiveness in preventing colon cancer

Oct 24, 2006

Dartmouth researchers are among a team of doctors that have learned more about how people may or may not benefit from taking aspirin in the effort to curb colon cancer. Their study, which appears in the Oct. 18 issue of the Journal of the National Cancer Institute, finds that the beneficial effect of aspirin may be limited to individuals who have a specific genetic variation in their ODC gene.

"There is evidence that aspirin and related anti-inflammatory drugs can reduce the risk of colorectal adenomas [polyps] and cancer," says Elizabeth Barry, a research assistant professor of community and family medicine at Dartmouth Medical School, and one the authors of the study. "And with this study, we looked closer at the impact of aspirin in people who have a higher risk of developing colorectal adenomas, which lead to cancer, by examining their ODC genotype. So now we know that aspirin appears to work better in people who have this slight genetic variation, and this finding could potentially be clinically useful in the future by allowing physicians to predict which individuals are likely to benefit from aspirin use for colorectal cancer chemoprevention."

The researchers studied 973 subjects over three years as part of the Aspirin/Folate Polyp Prevention Study. In a randomized manner, some were given aspirin and some were given placebos. Almost half of the participants carried one or two copies of the ODC genetic variation. The study found that there was no association between carrying the genetic variation and the occurrence or new adenomas, but the genotype did influence the effect of aspirin on adenoma development. Those with the ODC genetic variation were 23 percent less likely to develop new adenomas and 49 percent less likely to develop more advanced lesions, which also lead to cancer.

Other authors on the paper include John A. Baron and Maria V. Grau, with Dartmouth Medical School; Shubha Bhat and Thomas G. O'Brien, with the Institute for Medical Research in Wynnewood, Penn.; Carol A. Burke, with the Cleveland Clinic Foundation; Robert S. Sandler, with the University of North Carolina; Dennis J. Ahnen, with the University of Colorado Health Sciences Center in Denver; and Robert W. Haile, with the University of Southern California, Los Angeles.

Source: Dartmouth College

Explore further: Many older people have mutations linked to leukemia, lymphoma in their blood cells

add to favorites email to friend print save as pdf

Related Stories

Debate surrounds new prostate-cancer treatment

Aug 07, 2009

CyberKnife radiosurgery -- which uses narrow beams of radiation to kill several types of cancer -- is marketed as a less invasive, more convenient way to treat prostate cancer, a pitch that has proved convincing for about ...

A new century of Alzheimer's disease research

Jul 25, 2007

Imagine the day when a routine visit to the family doctor includes a simple blood test to predict the risk for developing Alzheimer’s disease (AD). If the test returns a worrisome result -- too many sticky brain proteins ...

Should patients undergoing surgery take Aspirin?

Oct 23, 2006

A national survey of Canadian surgeons by researchers at McMaster University found little consistency in their use of the blood thinner Aspirin in patients undergoing non-cardiac surgery.

Recommended for you

70-gene signature not cost-effective in breast cancer

Oct 18, 2014

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published ...

User comments : 0